{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:03:25Z","timestamp":1785351805407,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-04121-9","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:27:12Z","timestamp":1769581632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Melatonin in glioblastoma therapy: clinical promise and mechanistic insights from bench to bedside"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-4129","authenticated-orcid":false,"given":"Omar","family":"Alomari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyzanur","family":"G\u00fcney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Al","family":"Juhmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Alrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Edib","family":"Mokresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"8","key":"4121_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-oncology 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-oncology"},{"key":"4121_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"New Engl J Med"},{"key":"4121_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97\u2013109","journal-title":"Acta Neuropathol"},{"key":"4121_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.molonc.2010.08.001","volume":"4","author":"PB Dirks","year":"2010","unstructured":"Dirks PB (2010) Brain tumor stem cells: the cancer stem cell hypothesis writ large. Mol Oncol 4:420\u2013430. https:\/\/doi.org\/10.1016\/j.molonc.2010.08.001","journal-title":"Mol Oncol"},{"key":"4121_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7849890","volume":"2016","author":"BD Liebelt","year":"2016","unstructured":"Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J (2016) Glioma stem cells: signaling, microenvironment, and therapy. Stem Cells Int 2016:1\u201310. https:\/\/doi.org\/10.1155\/2016\/7849890","journal-title":"Stem Cells Int"},{"key":"4121_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2174\/1381612822666151214104941","volume":"22","author":"TV Beischlag","year":"2016","unstructured":"Beischlag TV, Anderson G, Mazzoccoli G (2016) Glioma: tryptophan catabolite and melatoninergic pathways link microRNA, 14-3- 3, chromosome 4q35, epigenetic processes and other glioma biochemical changes. Curr Pharm Des 22(8):1033\u20131048. https:\/\/doi.org\/10.2174\/1381612822666151214104941","journal-title":"Curr Pharm Des"},{"issue":"11","key":"4121_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/ph13110389","volume":"13","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Johanns TM, Ansstas G (2020) The landscape of novel therapeutics and challenges in glioblastoma multiforme: contemporary state and future directions. Pharmaceuticals 13(11):389","journal-title":"Pharmaceuticals"},{"key":"4121_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki T, Eltayeb M (2018) Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci 54:7\u201313","journal-title":"J Clin Neurosci"},{"key":"4121_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/jpi.12341","volume":"61","author":"X Chen","year":"2016","unstructured":"Chen X, Hao A, Li X, Du Z, Li H, Wang H, Yang H, Fang Z (2016) Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis. J Pineal Res 61:208\u2013217. https:\/\/doi.org\/10.1111\/jpi.12341","journal-title":"J Pineal Res"},{"key":"4121_CR10","doi-asserted-by":"publisher","first-page":"1414463","DOI":"10.3389\/fendo.2024.1414463","volume":"15","author":"RJ Reiter","year":"2024","unstructured":"Reiter RJ, Sharma R, Tan DX, Chuffa LGA, da Silva DGH, Slominski AT, Steinbrink K, Kleszczynski K (2024) Dual sources of melatonin and evidence for different primary functions. Front Endocrinol (Lausanne) 15:1414463. https:\/\/doi.org\/10.3389\/fendo.2024.1414463","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4121_CR11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00018-014-1579-2","volume":"71","author":"CD Acu\u00f1a","year":"2014","unstructured":"Acu\u00f1a CD, Escames G, Venegas C, D\u00edaz Casado ME, Lima Cabello E, L\u00f3pez LC, Rosales Corral S, Tan DX, Reiter RJ (2014) Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 71:2997\u20133025. https:\/\/doi.org\/10.1007\/s00018-014-1579-2","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4121_CR12","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/rmv.2499","volume":"34","author":"T Alomari","year":"2024","unstructured":"Alomari T, Al-Abdallat H, Hamamreh R, Alomari O, Hos BH, Reiter RJ (2024) Assessing the antiviral potential of melatonin: a comprehensive systematic review. Rev Med Virol 34(1):e2499. https:\/\/doi.org\/10.1002\/rmv.2499","journal-title":"Rev Med Virol"},{"key":"4121_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1517\/14728222.2013.834890","volume":"17","author":"M Bizzarri","year":"2013","unstructured":"Bizzarri M, Proietti S, Cucina A, Reiter RJ (2013) Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 17:1483\u20131496. https:\/\/doi.org\/10.1517\/14728222.2013.834890","journal-title":"Expert Opin Ther Targets"},{"key":"4121_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12526","author":"F Neamati","year":"2020","unstructured":"Neamati F, Asemi Z (2020) The effects of melatonin on signaling pathways and molecules involved in glioma. Fundam Clin Pharmacol. https:\/\/doi.org\/10.1111\/fcp.12526","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"4121_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/nu11061343","volume":"11","author":"SW Lai","year":"2019","unstructured":"Lai SW, Liu YS, Lu DY, Tsai CF (2019) Melatonin modulates the microenvironment of glioblastoma multiforme by targeting sirtuin 1. Nutrients 11(6):1343. https:\/\/doi.org\/10.3390\/nu11061343","journal-title":"Nutrients"},{"key":"4121_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12868-019-0545-1","volume":"20","author":"N Zhou","year":"2019","unstructured":"Zhou N, Wei ZX, Qi ZX (2019) Inhibition of autophagy triggers melatonin-induced apoptosis in glioblastoma cells. BMC Neurosci 20(1):63. https:\/\/doi.org\/10.1186\/s12868-019-0545-1","journal-title":"BMC Neurosci"},{"key":"4121_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11095-019-2662-z","volume":"36","author":"ER de Oliveira Junior","year":"2019","unstructured":"de Oliveira Junior ER, Nascimento TL, Salom\u00e3o MA, da Silva ACG, Valadares MC, Lima EM (2019) Increased nose-to-brain delivery of melatonin mediated by polycaprolactone nanoparticles for the treatment of glioblastoma. Pharm Res 36(9):131. https:\/\/doi.org\/10.1007\/s11095-019-2662-z","journal-title":"Pharm Res"},{"key":"4121_CR18","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 18:e1003583","journal-title":"PLoS Med"},{"key":"4121_CR19","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2020) Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: John Wiley & Sons. Available at: https:\/\/www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"4121_CR20","doi-asserted-by":"publisher","unstructured":"Min SN, Duangthip D, Detsomboonrat P (2024) QUIN tool (risk of bias tool for assessing in vitro studies).\u00a0PLOS ONE. Dataset.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0306367.t001","DOI":"10.1371\/journal.pone.0306367.t001"},{"key":"4121_CR21","unstructured":"National Heart, Lung and Blood Institute (2019) Study quality assessment tools. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"issue":"10","key":"4121_CR22","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Zachary1 Munn","year":"2020","unstructured":"Munn Zachary1, Barker Timothy Hugh1, Moola Sandeep1 2, Tufanaru Catalin1 3, Stern Cindy1, McArthur Alexa1, Stephenson Matthew1, Aromataris Edoardo1 (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"4121_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"1","key":"4121_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000069427","volume":"16","author":"P Lissoni","year":"1998","unstructured":"Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F (1998) Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 16(1):27\u201333. https:\/\/doi.org\/10.1159\/000069427","journal-title":"Nat Immun"},{"issue":"1","key":"4121_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000227533","volume":"53","author":"P Lissoni","year":"1996","unstructured":"Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53(1):43\u201346. https:\/\/doi.org\/10.1159\/000227533","journal-title":"Oncology"},{"issue":"2","key":"4121_CR26","first-page":"127","volume":"36","author":"G Di Bella","year":"2015","unstructured":"Di Bella G, Leci J, Ricchi A, Toscano R (2015) Recurrent glioblastoma multiforme (grade IV - WHO 2007): a case of complete objective response - concomitant administration of somatostatin \/ octreotide, retinoids, Vit E, Vit D3, Vit C, melatonin, D2 R agonists (Di Bella Method. Neuro Endocrinol Lett 36(2):127\u2013132","journal-title":"Neuro Endocrinol Lett"},{"issue":"7","key":"4121_CR27","first-page":"464","volume":"42","author":"G Di Bella","year":"2021","unstructured":"Di Bella G, Borghetto V, Costanzo E (2021) A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: a rationale and effectiveness. Neuroendocrinol Lett 42(7):464\u2013483","journal-title":"Neuroendocrinol Lett"},{"issue":"6","key":"4121_CR28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/sj.bjc.6603935","volume":"97","author":"A Gonz\u00e1lez","year":"2007","unstructured":"Gonz\u00e1lez A, Mart\u00ednez-Campa C, Mediavilla MD, Alonso-Gonz\u00e1lez C, S\u00e1nchez-Barcel\u00f3 EJ, Cos S (2007) Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br J Cancer 97(6):755\u2013760. https:\/\/doi.org\/10.1038\/sj.bjc.6603935","journal-title":"Br J Cancer"},{"issue":"10","key":"4121_CR29","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/bjc.2013.188","volume":"108","author":"V Mart\u00edn","year":"2013","unstructured":"Mart\u00edn V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antol\u00edn I, Rodriguez C (2013) Melatonin-induced methylation of the ABCG2\/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108(10):2005\u20132012. https:\/\/doi.org\/10.1038\/bjc.2013.188","journal-title":"Br J Cancer"},{"issue":"2","key":"4121_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jpi.12052","volume":"55","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Liu Q, Wang F, Ling EA, Liu S, Wang L, Yang Y, Yao L, Chen X, Wang F, Shi W, Gao M, Hao A (2013) Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1\u03b1. J Pineal Res 55(2):121\u2013130. https:\/\/doi.org\/10.1111\/jpi.12052","journal-title":"J Pineal Res"},{"issue":"3","key":"4121_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jpi.12170","volume":"57","author":"V Mart\u00edn","year":"2014","unstructured":"Mart\u00edn V, Sanchez-Sanchez AM, Puente-Moncada N, Gomez-Lobo M, Alvarez-Vega MA, Antol\u00edn I, Rodriguez C (2014) Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J Pineal Res 57(3):308\u2013316. https:\/\/doi.org\/10.1111\/jpi.12170","journal-title":"J Pineal Res"},{"key":"4121_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-015-0454-8","volume":"13","author":"CS Xu","year":"2015","unstructured":"Xu CS, Wang ZF, Huang XD, Dai LM, Cao CJ, Li ZQ (2015) Involvement of ROS-alpha v beta 3 integrin-FAK\/Pyk2 in the inhibitory effect of melatonin on U251 glioma cell migration and invasion under hypoxia. J Transl Med 13:95. https:\/\/doi.org\/10.1186\/s12967-015-0454-8","journal-title":"J Transl Med"},{"issue":"13Supplement","key":"4121_CR33","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1158\/1538-7445.AM2017-1498","volume":"77","author":"DG Franco","year":"2017","unstructured":"Franco DG, Moretti IF, Marie SK (2017) Melatonin inhibits mitochondrial transcription factor A expression in glioblastoma U87MG cell culture inducing an anti-tumorigenic effect. Cancer Res 77(13Supplement):1498\u20131498","journal-title":"Cancer Res"},{"issue":"36","key":"4121_CR34","doi-asserted-by":"publisher","first-page":"365102","DOI":"10.1088\/1361-6528\/aa7c76","volume":"28","author":"S Kumar Yadav","year":"2017","unstructured":"Kumar Yadav S, Kumar Srivastava A, Dev A, Kaundal B, Roy Choudhury S, Karmakar S (2017) Nanomelatonin triggers superior anticancer functionality in a human malignant glioblastoma cell line. Nanotechnology 28(36):365102. https:\/\/doi.org\/10.1088\/1361-6528\/aa7c76","journal-title":"Nanotechnology"},{"issue":"2","key":"4121_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7150\/ijbs.16818","volume":"13","author":"X Zheng","year":"2017","unstructured":"Zheng X, Pang B, Gu G, Gao T, Zhang R, Pang Q, Liu Q (2017) Melatonin inhibits glioblastoma stem-like cells through suppression of EZH2-NOTCH1 signaling axis. Int J Biol Sci 13(2):245\u2013253. https:\/\/doi.org\/10.7150\/ijbs.16818","journal-title":"Int J Biol Sci"},{"issue":"5","key":"4121_CR36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/molecules23051129","volume":"23","author":"DG Franco","year":"2018","unstructured":"Franco DG, Moretti IF, Marie SKN (2018) Mitochondria transcription factor A: a putative target for the effect of melatonin on U87MG malignant glioma cell line. Molecules 23(5):1129. https:\/\/doi.org\/10.3390\/molecules23051129","journal-title":"Molecules"},{"issue":"2","key":"4121_CR37","doi-asserted-by":"publisher","first-page":"e12496","DOI":"10.1111\/jpi.12496","volume":"65","author":"H Lee","year":"2018","unstructured":"Lee H, Lee HJ, Jung JH, Shin EA, Kim SH (2018) Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. J Pineal Res 65(2):e12496. https:\/\/doi.org\/10.1111\/jpi.12496","journal-title":"J Pineal Res"},{"issue":"2","key":"4121_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/medicines5020058","volume":"5","author":"DD McConnell","year":"2018","unstructured":"McConnell DD, McGreevy JW, Williams MN, Litofsky NS (2018) Do anti-oxidants vitamin D3, melatonin, and alpha-lipoic acid have synergistic effects with temozolomide on cultured glioblastoma cells? Medicines 5(2):58. https:\/\/doi.org\/10.3390\/medicines5020058","journal-title":"Medicines"},{"issue":"1","key":"4121_CR39","doi-asserted-by":"publisher","first-page":"e12478","DOI":"10.1111\/jpi.12478","volume":"65","author":"Z Yu","year":"2018","unstructured":"Yu Z, Tian X, Peng Y, Sun Z, Wang C, Tang N, Li B, Jian Y, Wang W, Huo X, Ma X (2018) Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin-induced apoptosis in neural cancer cells. J Pineal Res 65(1):e12478. https:\/\/doi.org\/10.1111\/jpi.12478","journal-title":"J Pineal Res"},{"issue":"Supplement1","key":"4121_CR40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuros\/nyz310_644","volume":"66","author":"BIF Gil","year":"2019","unstructured":"Gil BIF, Vazquez-Ramos CA, Schiapparelli P, Sarabia-Estrada R, Escames G, Quinones-Hinoja A (2019) Melatonin disrupts glioblastoma metabolism and enhances temozolomide cytotoxic effects. Neurosurgery 66(Supplement1):310\u2013644","journal-title":"Neurosurgery"},{"issue":"3","key":"4121_CR41","doi-asserted-by":"publisher","first-page":"e12556","DOI":"10.1111\/jpi.12556","volume":"66","author":"GJ Sung","year":"2019","unstructured":"Sung GJ, Kim SH, Kwak S, Park SH, Song JH, Jung JH, Kim H, Choi KC (2019) Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells. J Pineal Res 66(3):e12556. https:\/\/doi.org\/10.1111\/jpi.12556","journal-title":"J Pineal Res"},{"key":"4121_CR42","doi-asserted-by":"publisher","first-page":"101617","DOI":"10.1016\/j.tice.2021.101617","volume":"73","author":"O Do\u011fanlar","year":"2021","unstructured":"Do\u011fanlar O, Do\u011fanlar ZB, Delen E, Do\u011fan A (2021) The role of melatonin in angio-miR-associated inhibition of tumorigenesis and invasion in human glioblastoma tumour spheroids. Tissue Cell 73:101617. https:\/\/doi.org\/10.1016\/j.tice.2021.101617","journal-title":"Tissue Cell"},{"key":"4121_CR43","doi-asserted-by":"publisher","first-page":"113564","DOI":"10.1016\/j.ejmech.2021.113564","volume":"222","author":"X Fan","year":"2021","unstructured":"Fan X, Li J, Long L, Shi T, Liu D, Tan W, Zhang H, Wu X, Lei X, Wang Z (2021) Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma. Eur J Med Chem 222:113564. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113564","journal-title":"Eur J Med Chem"},{"issue":"2","key":"4121_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00109-020-02023-5","volume":"99","author":"GS Kinker","year":"2021","unstructured":"Kinker GS, Ostrowski LH, Ribeiro PAC, Chanoch R, Muxel SM, Tirosh I, Spadoni G, Rivara S, Martins VR, Santos TG, Markus RP, Fernandes PACM (2021) MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. J Mol Med 99(2):289\u2013301. https:\/\/doi.org\/10.1007\/s00109-020-02023-5","journal-title":"J Mol Med"},{"key":"4121_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jocn.2021.02.015","volume":"87","author":"C Wang","year":"2021","unstructured":"Wang C, Zhao Z, Qi Q, Wang J, Kong Y, Feng Z, Chen A, Li W, Zhang Q, Wang J, Huang B, Li X (2021) Mir-6858 plays a key role in the process of melatonin inhibition of the malignant biological behavior of glioma. J Clin Neuroscience: Official J Neurosurgical Soc Australasia 87:137\u2013146. https:\/\/doi.org\/10.1016\/j.jocn.2021.02.015","journal-title":"J Clin Neuroscience: Official J Neurosurgical Soc Australasia"},{"issue":"21","key":"4121_CR46","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/cells11213467","volume":"11","author":"BI Fernandez-Gil","year":"2022","unstructured":"Fernandez-Gil BI, Otamendi-Lopez A, Bechtle A, Vazquez-Ramos CA, Qosja N, Suarez-Meade P, Sarabia-Estrada R, Jentoft ME, Guerrero-C\u00e1zares H, Escames G, Schiapparelli P, Qui\u00f1ones-Hinojosa A (2022) Melatonin treatment triggers metabolic and intracellular pH imbalance in glioblastoma. Cells 11(21):3467. https:\/\/doi.org\/10.3390\/cells11213467","journal-title":"Cells"},{"issue":"1","key":"4121_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12967-021-03209-2","volume":"20","author":"WZ Lin","year":"2022","unstructured":"Lin WZ, Liu YC, Lee MC, Tang CT, Wu GJ, Chang YT, Chu CM, Shiau CY (2022) From GWAS to drug screening: repurposing antipsychotics for glioblastoma. J Transl Med 20(1):70. https:\/\/doi.org\/10.1186\/s12967-021-03209-2","journal-title":"J Transl Med"},{"issue":"1","key":"4121_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/1567202619666220406084947","volume":"19","author":"Z Yan","year":"2022","unstructured":"Yan Z, Zhang X, Hua L, Huang L (2022) Melatonin inhibits the malignant progression of glioblastoma via regulating miR-16-5p\/PIM1. Curr Neurovasc Res 19(1):92\u201399. https:\/\/doi.org\/10.2174\/1567202619666220406084947","journal-title":"Curr Neurovasc Res"},{"issue":"6","key":"4121_CR49","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/brainsci13060869","volume":"13","author":"M Hern\u00e1ndez-Cer\u00f3n","year":"2023","unstructured":"Hern\u00e1ndez-Cer\u00f3n M, Chavarria V, R\u00edos C, Pineda B, Palomares-Alonso F, Rojas-Tom\u00e9 IS, Jung-Cook H (2023) Melatonin in combination with albendazole or albendazole sulfoxide produces a synergistic cytotoxicity against malignant glioma cells through autophagy and apoptosis. Brain Sci 13(6):869. https:\/\/doi.org\/10.3390\/brainsci13060869","journal-title":"Brain Sci"},{"issue":"2","key":"4121_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15407\/exp-oncology.2024.02.087","volume":"46","author":"A Bostanci","year":"2024","unstructured":"Bostanci A, Doganlar O (2024) MELATONIN ENHANCES TEMOZOLOMIDE-INDUCED APOPTOSIS IN GLIOBLASTOMA AND NEUROBLASTOMA CELLS. Exp Oncol 46(2):87\u2013100. https:\/\/doi.org\/10.15407\/exp-oncology.2024.02.087","journal-title":"Exp Oncol"},{"key":"4121_CR51","doi-asserted-by":"publisher","first-page":"216920","DOI":"10.1016\/j.canlet.2024.216920","volume":"592","author":"F Wang","year":"2024","unstructured":"Wang F, Zhu Y, Wanggou S, Lin D, Su J, Li X, Tao E (2024) A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma. Cancer Lett 592:216920. https:\/\/doi.org\/10.1016\/j.canlet.2024.216920","journal-title":"Cancer Lett"},{"issue":"11","key":"4121_CR52","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","volume":"18","author":"PD Delgado-L\u00f3pez","year":"2016","unstructured":"Delgado-L\u00f3pez PD, Corrales-Garc\u00eda EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18(11):1062\u20131071. https:\/\/doi.org\/10.1007\/s12094-016-1497-x","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"4121_CR53","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/molecules26092506","volume":"26","author":"WH Talib","year":"2021","unstructured":"Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI (2021) Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. Molecules (Basel, Switzerland) 26(9):2506. https:\/\/doi.org\/10.3390\/molecules26092506","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"Suppl 1","key":"4121_CR54","first-page":"1","volume":"31","author":"G Di Bella","year":"2010","unstructured":"Di Bella G (2010) The Di Bella Method (DBM). Neuroendocrinol Lett 31(Suppl 1):1\u201342","journal-title":"Neuroendocrinol Lett"},{"issue":"7","key":"4121_CR55","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.3390\/ijms23073779","volume":"23","author":"L Wang","year":"2022","unstructured":"Wang L, Wang C, Choi WS (2022) Use of melatonin in cancer treatment: where are we? Int J Mol Sci 23(7):3779. https:\/\/doi.org\/10.3390\/ijms23073779","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4121_CR56","first-page":"425","volume":"27","author":"L Di Bella","year":"2006","unstructured":"Di Bella L, Gualano L (2006) Key aspects of melatonin physiology: thirty years of research. Neuroendocrinol Lett 27(4):425\u2013432","journal-title":"Neuroendocrinol Lett"},{"issue":"6","key":"4121_CR57","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.9.FOCUS14504","volume":"37","author":"EB Golden","year":"2014","unstructured":"Golden EB, Cho HY, Jahanian A, Hofman FM, Louie SG, Sch\u00f6nthal AH, Chen TC (2014) Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg Focus 37(6):E12. https:\/\/doi.org\/10.3171\/2014.9.FOCUS14504","journal-title":"Neurosurg Focus"},{"issue":"2","key":"4121_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00432-013-1565-3","volume":"140","author":"R Maga\u00f1a-Maldonado","year":"2014","unstructured":"Maga\u00f1a-Maldonado R, Manoutcharian K, Hern\u00e1ndez-Pedro NY, Rangel-L\u00f3pez E, P\u00e9rez-De la Cruz V, Rodr\u00edguez-Balderas C, Sotelo J, Pineda B (2014) Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma. J Cancer Res Clin Oncol 140(2):291\u2013301. https:\/\/doi.org\/10.1007\/s00432-013-1565-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4121_CR59","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/s41467-018-05261-x","volume":"9","author":"E Persi","year":"2018","unstructured":"Persi E, Duran-Frigola M, Damaghi M, Roush WR, Aloy P, Cleveland JL, Gillies RJ, Ruppin E (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9(1):2997. https:\/\/doi.org\/10.1038\/s41467-018-05261-x","journal-title":"Nat Commun"},{"issue":"2","key":"4121_CR60","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3892\/ol.2018.9758","volume":"17","author":"NM Sonehara","year":"2019","unstructured":"Sonehara NM, Lacerda JZ, Jardim-Perassi BV, de Paula R Jr, Moschetta-Pinheiro MG, Souza YST, de Andra JCJ, De Campos Zuccari DAP (2019) Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines. Oncol Lett 17(2):1635\u20131645. https:\/\/doi.org\/10.3892\/ol.2018.9758","journal-title":"Oncol Lett"},{"issue":"4","key":"4121_CR61","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1182\/blood.2021011563","volume":"139","author":"CH Man","year":"2022","unstructured":"Man CH, Mercier FE, Liu N, Dong W, Stephanopoulos G, Jiang L, Jung Y, Lin CP, Leung AYH, Scadden DT (2022) Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth. Blood 139(4):502\u2013522. https:\/\/doi.org\/10.1182\/blood.2021011563","journal-title":"Blood"},{"key":"4121_CR62","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/sigtrans.2016.47","volume":"2","author":"X Hu","year":"2017","unstructured":"Hu X, Chao M, Wu H (2017) Central role of lactate and proton in cancer cell resistance to glucose deprivation and its clinical translation. Signal Transduct Target Ther 2:16047. https:\/\/doi.org\/10.1038\/sigtrans.2016.47","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4121_CR63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/jcb.25653","volume":"118","author":"M Torrens-Mas","year":"2017","unstructured":"Torrens-Mas M, Pons DG, Sastre-Serra J, Oliver J, Roca P (2017) Sirt3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production. J Cell Biochem 118(2):397\u2013406. https:\/\/doi.org\/10.1002\/jcb.25653","journal-title":"J Cell Biochem"},{"issue":"4","key":"4121_CR64","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3325\/cmj.2021.62.376","volume":"62","author":"D Ore\u0161kovi\u0107","year":"2021","unstructured":"Ore\u0161kovi\u0107 D, Ka\u0161telan\u010di\u0107 A, Ragu\u017e M, Dlaka D, Predrijevac N, Matec D, Matec M, Tomac D, Jele\u010d V, Marinovi\u0107 T, Chudy D (2021) The vicious interplay between disrupted sleep and malignant brain tumors: a narrative review. Croat Med J 62(4):376\u2013386. https:\/\/doi.org\/10.3325\/cmj.2021.62.376","journal-title":"Croat Med J"},{"key":"4121_CR65","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1017\/erm.2022.15","volume":"24","author":"M Ghareghani","year":"2022","unstructured":"Ghareghani M, Zibara K, Reiter RJ, Rivest S (2022) Reduced melatonin levels may facilitate glioblastoma initiation in the subventricular zone. Expert Rev Mol Med 24:e24. https:\/\/doi.org\/10.1017\/erm.2022.15","journal-title":"Expert Rev Mol Med"},{"issue":"3","key":"4121_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cell.2020.12.026","volume":"184","author":"A Gengatharan","year":"2021","unstructured":"Gengatharan A, Malvaut S, Marymonchyk A, Ghareghani M, Snapyan M, Fischer-Sternjak J, Ninkovic J, G\u00f6tz M, Saghatelyan A (2021) Adult neural stem cell activation in mice is regulated by the day\/night cycle and intracellular calcium dynamics. Cell 184(3):709\u2013722.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.12.026","journal-title":"Cell"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04121-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-04121-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04121-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:27:16Z","timestamp":1769581636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-04121-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-04121-9","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"165"}}